CLSA was greatly honored to welcome Dr. Robert Califf as the keynote speaker at our recent Evening with Thought Leaders in Los Angeles. Dr. Califf has had an extraordinarily impressive career as a cardiologist, Commissioner of the Food & Drug Administration (FDA), and now as a researcher with Duke University and advisor at Verily, an Alphabet company.
In recent years, a new round of terrifying viruses has captured the public’s imagination. Ebola, H1N1, SARS, Zika and other pathogens strike rapidly, mutate without warning and pose a major threat to public health. We recently chatted with PaxVax CEO Nima Farzan about how we can better unite government and industry to prepare for these dangers.
Our President & CEO Sara Radcliffe provides an update on some of the other key happenings at CLSA.
CLSA Member Synergy Health hosted a facility preview event on June 30 for the newest expansion set in Petaluma, Sonoma County, CA.
Last week, CLSA Member Vertex Pharmaceuticals received FDA approval to treat Cystic Fibrosis. The approval is a shift away from prevoius CF treatments, and it addresses the underlying cause of the disease according to our partners at Biotech Primer. In their weekly email to subscribers, Biotech Primer said Vertex shifted the paradigm of treating cystic fibrosis (CF) … Continue reading A Biotech’s Treatment Changes the Game
The 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production from BioPlan Associates, Inc., provides global analysis of biopharma trends, based on input from 237 biomanufacturers and 164 suppliers in 28 countries. The 12th Annual Report and survey is the industry’s definitive, quantitative analysis and includes 12 years of biopharma trends analysis and … Continue reading Biosimilars, Outsourcing Impact Biopharma Manufacturing Production
CLSA members RoseRyan, Medivation, and ABD Team were recognized by the Bay Area News Group as one of the Top 100 Workplaces in the region.
The PCSK9 inhibitor buzz keeps rolling, especially since sitting before the FDA Advisory Committee earlier this month. Our friends at BiotechPrimer explain the science behind two of treatments.
Smart, connected medical devices are now technologically and economically feasible. A new report from Deloitte Center for Health Solutions looks how an increasingly intelligent future will reshape the MedTech industry.
CLSA is committed to providing one robust, unified voice for California’s statewide life sciences sector, which works tirelessly to drive transformative innovation that will benefit patients and consumers in the U.S. and around the world for years to come.
CLSA’s Sara Radcliffe joins Congressman Joe Barton, NIH Director Dr. Francis Collins, Celgene Chairman & CEO Robert Hugin and Milken Institute Chairman Michael Milken to discuss maintaining and accelerating U.S. leadership in medical research and innovation.
By examining the impact technology has had on industries such as banking, retail and education, the vision of connected health is a new avenue of an already successful pairing. Physicians and health providers pushing for better access to higher quality and more efficient care, as well as the changing healthcare economy have given rise to … Continue reading Join CHI at the 2015 Convergence Summit
Meet with fellow technology CEOs, executives, entrepreneurs, and strategic advisors from across Southern California Make valuable connections and build relationships with tech VCs and investors See the most innovative startup companies from the Southern California region Learn from industry experts on current hot topics during keynotes and panel sessions Visit over 50 high technology companies … Continue reading Top 5 Reasons You Should Attend OCTANe’s Technology Investor Forum
The Reality of Prescription Drug Spending in Medicaid From our partners at PhRMA By Robert Zirkelbach April 9, 2015 Recent rhetoric on spending in state Medicaid programs often overstates the cost impact of prescription medicines and ignores the competitive biopharmaceutical market that exists in the U.S., which can generate significant savings for Medicaid programs. Prescription … Continue reading The Reality of Prescription Drug Spending in Medicaid
Posted by Sara Radcliffe, President & CEO April 1, 2015 AN ACTION-PACKED FIRST MONTH! Our new organization, the California Life Sciences Association, is well on the way to becoming California’s most influential life sciences advocacy and business leadership organization. The merger between the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) closed … Continue reading CHI & BayBio Update from the President’s Desk
Insurance practices create barriers to life-saving medications, undermine effective health care By Sara Radcliffe, Op-Ed Special to The Sacramento Bee March 29, 2015 Every day advances in medical innovation saves lives. Patients who just a few years ago might have died from cancer, heart disease or HIV/AIDS can turn the page and continue productive lives. … Continue reading Sacramento Bee: Opinion: Insurance practices create barriers to life-saving medications, undermine effective health
What Access and Affordability Means for Chronic Disease Patients From our partners at PhRMA March 12, 2015 By Allyson Funk For the nearly one in two American adults living with at least one chronic illness, affordability and access to medicine is crucial. Unfortunately, if you have a chronic condition, there may be unexpectedly high upfront costs to access … Continue reading What Access and Affordability Means for Chronic Disease Patients